Quipt Home Medical Corp. (QIPT Q4 FY2024 earnings call

• Fiscal 2024 achieved record revenue of $245.9 million, 16% YOY growth, and adjusted EBITDA of $57.9 million, 14% YOY growth with 23.5% margin.
• Q4 2024 returned to positive sequential organic growth of 1%.
• Transitioned from IFRS to GAAP, with bad debt expense now included in revenue.
• Sleep business: GLP-1 medications have no negative impact on demand; referral activity steady, replacement supply strong.
• Ongoing civil investigative demand (CID); CMS announced positive CPI adjustments for 2025 fee schedules.
• M&A landscape dynamic with opportunities aligning with acquisition criteria; net leverage at 1.6 times.

Respiratory care represents approximately 80% of the product mix. For fiscal 2024, revenue was $245.9 million, a 16% year-over-year growth. Respiratory resupply set-ups and deliveries increased to 480,000 for the year ended September 30, 2024 compared to 396,000 in 2023, reflecting a 21% growth. The customer base grew 10% year-over-year to 314,000 unique patients. Unique set-ups/deliveries in fiscal 2024 were 854,000, an increase of 13% from 2023.

• Expect return to historical organic growth rate in calendar 2025.
• Fiscal 2025 guidance for 6%-8% free cash flow (non-GAAP).
• Confident in driving sustainable organic growth, expanding adjusted EBITDA margins, and strengthening nationwide healthcare network.

• Ongoing civil investigative demand (CID) with uncertainty around resolution and costs.
• Impact of industry-wide challenges like Medicare 75/25 expiration and Humana capitation agreement.
• Change Healthcare cyber attack impact on collections.

Q: Richard Close asked about organic growth in fiscal '25, CID costs, and cash from operations change.

A: Hardik Mehta said organic growth rates should start to align with historical levels, CID costs are hard to project, and cash flow change is related to lease classification from finance to operating.

Q: Bill Sutherland inquired about fiscal 4Q growth adjustment for headwinds.

A: Hardik Mehta explained the $5 million impact from 75/25 and Humana on year-over-year growth.

Q: Julian Hung asked about DOJ investigation and diabetes business update.

A: Greg Crawford discussed ongoing DOJ CID investigation and diabetes business growth with margin impact.

Q: Doug Cooper questioned EBITDA margins and M&A pricing.

A: Greg Crawford and Hardik Mehta talked about margin adjustments due to cost structures and favorable M&A pricing